DAVIS & HARMAN LLP for EMERGENT BIOSOLUTIONS, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Disaster Planning/Emergencies DIS
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical Countermeasures. H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS A DAVIS | — |
Budget/Appropriations BUD
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical Countermeasures. H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS A DAVIS | — |
Homeland Security HOM
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act. NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical Countermeasures. H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS A DAVIS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.